List of Excipients in Branded Drug DYE FREE WAL FEX

Generic Drugs Containing DYE FREE WAL FEX

Company	Ingredient	NDC	Excipient
Walgreens	fexofenadine hcl	0363-9230	BUTYLPARABEN
Walgreens	fexofenadine hcl	0363-9230	EDETATE DISODIUM
Walgreens	fexofenadine hcl	0363-9230	POLOXAMER 407

What are the Most Frequently-Used Excipients in DYE FREE WAL FEX?

# Of NDCs	Excipient
1	BUTYLPARABEN
1	EDETATE DISODIUM
1	POLOXAMER 407

DYE-FREE WAL-FEX: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 6, 2026

Dye-Free Wal-Fex is an over-the-counter fexofenadine hydrochloride product positioned around non-dyed oral solid dosing. Its commercial value comes from low-cost generic manufacturing, broad allergy demand, retail-channel distribution and consumer preference for simpler excipient profiles. The core active ingredient is mature and exposed to substantial generic competition, so differentiation depends on excipient tolerability, tablet performance, packaging, retail placement and price.

The strongest commercial opportunity is a disciplined dye-free platform for fexofenadine 180 mg and related allergy products. The main risks are limited formulation exclusivity, retailer price competition, supplier concentration and the need to substantiate any consumer-facing claims about allergens or excipient absence.

What is Dye-Free Wal-Fex?

Dye-Free Wal-Fex is a retail-brand oral product containing fexofenadine hydrochloride, a second-generation H1 antihistamine used for relief of seasonal allergic rhinitis symptoms and chronic idiopathic urticaria. Wal-Fex products are generally positioned as store-brand alternatives to Allegra and other fexofenadine products.

The product’s differentiation is the absence of color additives in the tablet or coating. “Dye-free” does not mean excipient-free. The formulation still requires functional materials for compression, binding, disintegration, lubrication, coating, stability and dose uniformity.

Product profile

Attribute	Commercial assessment
Active ingredient	Fexofenadine hydrochloride
Therapeutic category	Second-generation antihistamine
Typical OTC strength	180 mg once daily for adults and children 12 years and older, depending on labeling
Dosage form	Immediate-release oral tablet or caplet
Primary indication	Seasonal allergic rhinitis
Differentiation	Dye-free excipient profile and private-label pricing
Reference brand	Allegra and related fexofenadine products
Regulatory pathway	OTC product supported by FDA labeling and applicable OTC requirements
Biosimilar exposure	None; fexofenadine is a small-molecule drug
Principal commercial risk	Generic price compression and limited formulation exclusivity

Fexofenadine is the active carboxylic-acid metabolite of terfenadine. It does not have the same historical cardiac safety profile associated with terfenadine because it is not converted to terfenadine’s cardiotoxic metabolite under normal use conditions. FDA labeling identifies fexofenadine as a non-sedating antihistamine, although individual responses can vary. [1]

What excipients are likely used in Dye-Free Wal-Fex?

A dye-free fexofenadine tablet normally uses conventional oral-solid excipients rather than novel delivery technology. The exact inactive-ingredient list depends on the manufacturer, dosage strength, tablet architecture and current National Drug Code presentation. Product-specific labeling remains the controlling source for the marketed formulation.

Typical excipient functions include:

Excipient category	Typical function	Strategic relevance
Microcrystalline cellulose	Diluent and compression aid	Supports robust tablet manufacture
Pregelatinized starch or other starch	Binder and disintegrant	Improves mechanical strength and breakup
Croscarmellose sodium or sodium starch glycolate	Superdisintegrant	Controls tablet disintegration
Povidone	Binder	Improves granulation and content uniformity
Colloidal silicon dioxide	Glidant	Improves powder flow
Magnesium stearate	Lubricant	Reduces tablet ejection force
Hypromellose	Film-coating polymer	Provides surface protection and swallowability
Polyethylene glycol	Coating plasticizer	Improves coating flexibility
Titanium dioxide or mineral opacifier	Opacity and appearance	Requires careful review in dye-free positioning
Purified water	Processing solvent	Removed during drying

A dye-free product may still use a white or opaque film coating. Manufacturers should define the claim precisely: absence of synthetic color additives, absence of FD&C dyes, or absence of all colorants. Those statements are not interchangeable.

Which excipient choices create the most value?

The highest-value excipient decisions are those that improve manufacturing reliability without increasing tablet size or creating new tolerability concerns.

A preferred platform would use:

1. A direct-compression or dry-granulation process to reduce solvent use and processing time.
2. A low-level superdisintegrant system that delivers rapid tablet breakup without excessive friability.
3. A low-moisture excipient system because fexofenadine hydrochloride products must maintain dissolution and physical stability through shelf life.
4. A coating system with no FD&C or D&C dyes.
5. Excipients with multiple qualified suppliers to reduce supply disruption.
6. A short inactive-ingredient list that supports clear consumer communication.

The active dose is relatively high for an antihistamine tablet, so tablet mass and swallowability are important. Excessive filler loading can produce a large caplet, while aggressive compression can slow disintegration. Formulation development should balance tablet hardness, friability, dissolution, coating weight and ease of swallowing.

How should a dye-free fexofenadine excipient strategy be designed?

A commercially effective strategy should treat “dye-free” as one element of a broader excipient-control program.

Formulation design

The development target should include:

• Rapid and reproducible disintegration.
• Dissolution comparable with the reference or applicable regulatory standard.
• Low friability during packaging and distribution.
• No synthetic dyes in the core or coating.
• No avoidable excipients that create consumer objections.
• Stable performance under elevated temperature and humidity.
• Compatibility with high-speed compression and coating equipment.

Fexofenadine tablets are immediate-release products. A modified-release or orally disintegrating platform would require a different regulatory and competitive analysis. The commercial justification for such a platform would need to exceed the cost and regulatory burden of a conventional tablet.

Excipient risk control

The formulation team should assess:

• Lactose status, especially for lactose-avoidance claims.
• Gluten status and the source of starch-based excipients.
• Animal-derived materials.
• Residual solvents and elemental impurities.
• Nitrosamine and other impurity risks arising from excipient or process inputs.
• Magnesium stearate variability and its impact on dissolution.
• Coating opacity and whether any opacifier conflicts with consumer expectations.
• Supplier changes and their effect on dissolution, hardness or stability.

“Free-from” claims require evidence and controlled supplier documentation. A formulation should not be marketed as allergen-free, gluten-free or preservative-free unless the relevant claim is supported by the complete composition and applicable labeling requirements.

What FDA regulatory status applies to Dye-Free Wal-Fex?

Fexofenadine is marketed in the United States through OTC products and generic equivalents. FDA-approved fexofenadine products use established labeling for allergy indications and age restrictions. The final legal status of a specific Wal-Fex package depends on its manufacturer, NDC, labeling and regulatory pathway.

FDA review focuses on active ingredient identity, strength, dosage form, labeling, manufacturing controls, product quality and compliance with the applicable OTC framework or approved application. Dye-free status is a formulation and labeling attribute, not a separate therapeutic indication. [2]

What does the Orange Book show?

The FDA Orange Book is relevant where a specific fexofenadine product is approved under an NDA or ANDA and where listed patents or exclusivities affect approval or marketing. [3]

For mature fexofenadine products, the original new-drug and formulation barriers have largely expired. The current competitive environment is dominated by generic and private-label products. Any active patent issue must be assessed at the specific product and NDC level because a broad review of the active ingredient does not establish the status of every marketed formulation.

Commercial diligence should review:

• NDA and ANDA approval records.
• Listed patents, if any.
• Pediatric exclusivity records.
• Labeling differences.
• Product-specific therapeutic equivalence codes.
• Discontinued or obsolete presentations.
• Patent certifications associated with pending generic applications.

When does fexofenadine lose exclusivity?

Fexofenadine’s original small-molecule exclusivity period is no longer the principal commercial barrier. The product has been subject to generic competition for many years, and the market includes multiple manufacturers and store-brand alternatives.

There is no biosimilar exclusivity issue because fexofenadine is not a biologic. The relevant entry mechanisms are ANDA approval, OTC compliance, product-specific labeling and manufacturing capability.

Are Paragraph IV challenges still relevant?

Paragraph IV litigation is less important for a mature fexofenadine product than it was during the original generic-entry period. Paragraph IV certification remains legally relevant when a pending ANDA applicant challenges an unexpired listed patent. In practice, the commercial question is whether any enforceable patent continues to block a particular presentation.

For a dye-free fexofenadine tablet, the likely barriers are:

• Manufacturing scale.
• Retailer qualification.
• Product quality and supply reliability.
• Packaging and launch timing.
• Consumer acquisition cost.
• Contract manufacturing capacity.

A new formulation patent could create a separate issue, but a conventional dye-free tablet using established excipients is unlikely to support a broad, durable exclusivity position on its own.

What patents protect Dye-Free Wal-Fex?

The product’s active ingredient is not protected by a current new-molecule patent moat. Any patent analysis should distinguish among four categories:

Patent category	Relevance to Dye-Free Wal-Fex
Composition-of-matter patents	Historical relevance; unlikely to block current conventional products
Formulation patents	Potentially relevant only if the product uses a distinctive patented composition
Method-of-use patents	Limited relevance for standard OTC allergy labeling
Manufacturing patents	Relevant only if the process uses a proprietary, non-obvious method

A simple absence-of-dye formulation is difficult to protect broadly unless it includes a specific excipient ratio, stability advantage, dissolution profile or manufacturing process that satisfies patentability requirements. Even then, enforcement would depend on claim scope and the ability to prove infringement from public product information.

The strongest protectable opportunities are more likely to involve:

• A compact high-dose tablet with improved swallowability.
• A taste-masked orally disintegrating dosage form.
• A low-moisture formulation with improved stability.
• A specific coating system that avoids dyes while improving mechanical protection.
• A pediatric formulation with clinically justified dosing and acceptable taste.
• A combination product with a separate regulatory and claim strategy.

What commercial opportunities exist for Dye-Free Wal-Fex?

Private-label retail expansion

The clearest opportunity is expansion across pharmacy, grocery, club, dollar and e-commerce channels. Retailers can use a common formulation platform with channel-specific packaging and pricing.

A manufacturer can offer:

• 30-count and 90-count bottles.
• Seasonal allergy multipacks.
• Store-brand equivalents to branded fexofenadine.
• E-commerce-focused multipacks.
• Unit-dose or blister presentations for travel.
• Retailer-exclusive packaging with the same approved formulation.

The product’s value proposition is strongest where shoppers compare price, active ingredient and inactive ingredients directly.

Sensitive-consumer positioning

Dye-free positioning can appeal to consumers who avoid artificial colors or prefer shorter ingredient lists. The claim has commercial value when presented accurately and paired with transparent labeling.

Potential supporting claims include:

• Dye-free.
• No artificial color.
• Once-daily allergy relief, where consistent with approved labeling.
• Non-drowsy or less-sedating positioning, subject to label language.
• Gluten-free or lactose-free only when substantiated.

The claim should not imply that the product is safer or more effective than other fexofenadine products solely because it lacks dyes.

Formulation line extensions

A platform can support additional products, subject to regulatory and clinical requirements:

Extension	Opportunity	Main barrier
Fexofenadine 60 mg	Flexible dosing and broader family use	Labeling and age-specific directions
Fexofenadine 30 mg	Pediatric or lower-dose positioning	Pediatric safety and formulation requirements
Orally disintegrating tablet	Swallowability differentiation	Taste masking and stability
Liquid formulation	Pediatric and swallowing-impaired users	Preservatives, taste and microbial control
24-hour 180 mg tablet	Core high-volume product	Price and retailer competition
Seasonal multipack	Higher basket size	Inventory and demand seasonality
Combination allergy product	Broader symptom coverage	Additional active ingredients and regulatory complexity

A liquid or orally disintegrating format may create more meaningful differentiation than a standard dye-free caplet, but it also introduces greater formulation and regulatory risk.

How does Dye-Free Wal-Fex compare with Allegra and other fexofenadine products?

Factor	Dye-Free Wal-Fex	Allegra	Other generic fexofenadine
Active ingredient	Fexofenadine hydrochloride	Fexofenadine hydrochloride	Fexofenadine hydrochloride
Core efficacy	Expected to depend on equivalent active ingredient and labeled dose	Reference-brand positioning	Generic-equivalent positioning
Dye-free positioning	Primary differentiator	Depends on specific presentation	Varies by manufacturer
Price	Typically lower	Typically higher	Competitive
Brand investment	Retailer or private-label support	National consumer marketing	Usually limited
Patent protection	Limited conventional-formulation protection	Historical brand and formulation rights	Limited
Retail flexibility	High for private-label contracts	Controlled by brand owner	Depends on supplier
Consumer trust	Driven by retailer and label transparency	Driven by national brand	Driven by price and pharmacy familiarity

The commercial battle is therefore based on price, availability, pack size and perceived ingredient simplicity rather than meaningful differentiation in the active pharmaceutical ingredient.

What manufacturing and supply-chain barriers exist?

The technical process is comparatively accessible, but scale economics matter. Key barriers include:

• Consistent supply of pharmaceutical-grade fexofenadine hydrochloride.
• Validated analytical methods for assay, impurities and dissolution.
• Tablet compression at high production volumes.
• Coating uniformity without dyes.
• Stability across seasonal inventory cycles.
• Packaging that limits moisture and protects tablet integrity.
• Dual sourcing for critical excipients.
• Retailer service levels during peak allergy season.

A supplier should qualify at least two sources for major excipients and maintain change-control procedures that evaluate dissolution and stability after any material change. Seasonal demand creates a risk of overproduction after spring and summer peaks, while stockouts can cause retailer delisting.

What litigation and settlement risks affect the product?

There is no inherent litigation exposure merely from marketing a dye-free fexofenadine tablet. Risk increases if the product copies a protected formulation, uses disputed labeling, makes unsupported free-from claims or enters a market while a relevant listed patent remains enforceable.

A diligence program should review:

• Orange Book listings for the relevant reference product.
• ANDA patent certifications.
• Historical fexofenadine patent litigation.
• Trademark rights associated with “Wal-Fex.”
• Retailer indemnification terms.
• Product-liability and labeling claims.
• Supplier warranties for excipient identity and allergen status.

The “Wal-Fex” name is a private-label trademark and should be analyzed separately from pharmaceutical patent rights.

What is the revenue opportunity for a dye-free fexofenadine platform?

Revenue potential depends on retailer access, price, market share and pack configuration. The product is attractive because fexofenadine has established consumer recognition and recurring seasonal demand. The limitations are low switching costs and extensive generic competition.

The most defensible commercial model is:

1. Secure one or more large retail or pharmacy contracts.
2. Use a common validated formulation across multiple pack sizes.
3. Maintain a low-cost manufacturing process.
4. Add a dye-free claim supported by controlled composition records.
5. Expand into adjacent strengths or dosage forms only after the base product reaches stable volume.
6. Use multipacks and e-commerce formats to increase units per transaction.

A premium over undifferentiated generic fexofenadine is possible, but the premium must be supported by clear labeling, reliable supply and credible retailer positioning.

Key Takeaways

• Dye-Free Wal-Fex is a fexofenadine hydrochloride OTC product differentiated primarily by its inactive-ingredient profile.
• The formulation should prioritize rapid dissolution, tablet robustness, low moisture sensitivity and a clear dye-free definition.
• Fexofenadine has no biosimilar risk and no meaningful new-molecule patent barrier for current conventional products.
• Formulation patents are possible but difficult to obtain broadly for a standard dye-free tablet using known excipients.
• The strongest commercial channels are private-label pharmacy, grocery, club, e-commerce and seasonal multipack programs.
• Orally disintegrating, liquid and pediatric formats offer greater differentiation but introduce higher regulatory and technical costs.
• Manufacturing scale, supplier qualification and seasonal inventory management are more important than patent exclusivity for current market entry.
• Any “free-from” claim must be supported by the complete excipient composition and supplier controls.

FAQs

Is Dye-Free Wal-Fex the same active ingredient as Allegra?

Yes. The product uses fexofenadine hydrochloride, although inactive ingredients, tablet design, packaging and labeling may differ by manufacturer and presentation.

Can a manufacturer patent a dye-free fexofenadine tablet?

Possibly, but a broad patent based only on removing color additives would face significant patentability challenges. Stronger claims would require a specific composition, process, stability result or dissolution advantage.

Does dye-free fexofenadine have a biosimilar competitor?

No. Fexofenadine is a small-molecule drug. Competition occurs through generic and OTC pathways rather than biosimilar approval.

Is a dye-free claim enough to justify a higher retail price?

Usually not by itself. Pricing power is stronger when the claim is combined with retailer trust, transparent excipient disclosure, reliable supply, convenient pack sizes or a differentiated dosage form.

What is the best next product after a dye-free 180 mg tablet?

A 90-count value pack or a carefully developed orally disintegrating product is generally more commercially logical than a complex combination product. The former improves retail economics, while the latter may create a clearer consumer benefit but carries higher development and regulatory risk.

References

1. U.S. Food and Drug Administration. (n.d.). Fexofenadine hydrochloride product labeling. DailyMed. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Over-the-counter drug monograph and labeling requirements. https://www.fda.gov/drugs/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2016). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/
5. U.S. Food and Drug Administration. (n.d.). Generic drugs: Questions and answers. https://www.fda.gov/drugs/generic-drugs/ generic-drugs-questions-answers